Moreover, we show that doxorubicin-induced NF-κB activity in sarcomas is transcriptionally active and that targeted inhibition of canonical NF-κB activation enhances the cytotoxic effects of doxorubicin through increased apoptotic cell death. This evidence concerns the gene NFKB1 and sarcoma.